Page 4 - Contract Testing Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Net Profit Attributable to Owners of the Company Up 394.9% Year-over-Year to RMB1.50 Billion Diluted EPS Up 369.2% Year-Over-Year to RMB0.61 Adjusted Diluted Non-IFRS EPS Up 52.0% Year-Over-Year to RMB0.38 [1] SHANGHAI, April 29, 2021 /PRNewswire/ WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 ( Reporting Period ). All financials disclosed in this press release are prepared based on International Financial Reporting Standards (or IFRSs ), in currency of RMB.

Contract testing developmentInternational financial reporting standardsOwners of the companyLaboratory servicesManufacturing organizationFee for servicesChina securities regulatory commissionPrnewswire wuxi apptec co ltdNational medical products administrationClinical researchAccounting standard for business enterprisesProfit attributableReporting periodAccounting standardsBusiness enterprisesBased laboratory services